Semaxanib

CAS No. 194413-58-6

Semaxanib ( SU5416 )

Catalog No. M13045 CAS No. 194413-58-6

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 102 In Stock
10MG 178 In Stock
25MG 314 In Stock
50MG 538 In Stock
100MG 659 In Stock
200MG 897 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Semaxanib
  • Note
    Research use only, not for human use.
  • Brief Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
  • Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SU5416
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2/Flk1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    194413-58-6
  • Formula Weight
    238.28
  • Molecular Formula
    C15H14N2O
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
  • SMILES
    CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.
molnova catalog
related products
  • BFH-772

    A potent, selective and orally active VEGFR2 tyrosine kinase inhibitor with IC50 of 3 nM.

  • AKB-6899

    AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages.

  • Asimadoline hydrochl...

    Asimadoline HCl is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline has also been shown to be used in the treatment of irritable bowel syndrome.